Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Earnings data Q3 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, July  17, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced presentations covering the AT-007 Galactosemia development program at the Galactosemia Foundation 2020 Virtual Conference, July 17-19. The Galactosemia Foundation Conference is a unique platform that brings together patients and families with Galactosemia alongside researchers and physicians.

Applied Therapeutics to Present Data on AT-007 for Treatment of Galactosemia at the Galactosemia Foundation 2020 Virtual Conference

On July 1, 2020, a fraudulent “short report” was posted.

Applied Therapeutics Takes Action Against Fraudulent “Short Report”

Applied Therapeutics (APLT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Applied Therapeutics (APLT) Stock Might be a Great Pick

Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Applied Therapeutics Inc. (APLT) Moves to Strong Buy: Rationale Behind the Upgrade

AT-007 pediatric Galactosemia study (ACTION-Galactosemia Kids) initiated

Applied Therapeutics Announces Start of AT-007 Pediatric Galactosemia Study; Releases Additional 40mg/kg Data from Adult Galactosemia Study

NEW YORK, June  08, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that three abstracts have been selected, including one oral presentation, at  the upcoming American Diabetes Association’s (ADA) 80th Scientific Sessions: A Virtual Experience taking place June 12-16, 2020. The abstracts and presentation include data on the safety and tolerability of Applied Therapeutics’ investigational candidate for Diabetic Cardiomyopathy (DbCM), AT-001, a next generation aldose reductase inhibitor (ARI).

Applied Therapeutics to Present Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at 2020 American Diabetes Association Virtual Scientific Sessions

NEW YORK, May  26, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today the appointment of Dr. Charles (Chuck) Silberstein, MD, MBA, CFA as Chief Financial Officer and Head of Business Development, effective immediately.  Dr. Silberstein is replacing Dr. Mark Vignola, who will be moving on to pursue new business opportunities.  

Applied Therapeutics Announces Appointment of Dr. Chuck Silberstein, MD, MBA, CFA as Chief Financial Officer and Head of Business Development

New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patients

Applied Therapeutics Announces IND and Investigator-Initiated Studies of AT-001 in Critical COVID-19 Patients

Applied Therapeutics: This Is A Good Entry Point

NEW YORK, March  03, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today announced the appointment of Adam Hansard as Chief Commercial Officer. Mr. Hansard brings extensive experience across the biotech and pharmaceutical industry to Applied Therapeutics, ranging from rare disease to large commercial indications.

Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer

Community Health Systems

Enphase Energy

Fulgent Genetics

Tandem Diabetes Care

Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.

5 Top-Ranked Stocks Beating the Market at Midway Q1

Abeona Therapeutics

Ennis

Onconova Therapeutics

Proteostasis Therapeutics

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

US Dollar Flexes Muscles Against Other Currencies: 5 Winners

Adaptimmune Therapeutics

Kiniksa Pharmaceuticals Ltd

These three clinical-stage biotechs could all double in value before year's end.

3 Top Biotech Stocks to Buy in February

Cardlytics

EverBank Financial

FuelCell Energy

Hovnanian Enterprises

Hovnanian Enterprises, Inc. Pfd Shs Series A

While the record rally in Tesla stock has garnered all the attention over the past six months, these growth stocks have been just as hot.

5 Growth Stocks That Are as Hot as Tesla

NEW YORK, Jan.  28, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has completed its public offering of 3,152,712 shares of its common stock.  The offering consisted of 3,152,712 shares of common stock, including the exercise in full of the underwriters’ option to purchase 411,223 additional shares of common stock.  The shares were offered at a price to the public of $45.50 per share, resulting in aggregate gross proceeds of approximately $143.4 million, before deducting underwriting discounts and commissions and estimated offering expenses. 

Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock

NEW YORK, Jan.  23, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of its public offering of 2,741,489 shares of its common stock, par value $0.0001 per share, at a price to the public of $45.50 per share. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $124.7 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 411,223 shares of common stock at the price to the public, less underwriting discounts and commissions. The offering was upsized from the previously announced offering size of 1,750,000 shares of common stock. 

Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock

NEW YORK, Jan.  21, 2020  (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of 1,750,000 shares of its common stock, par value $0.0001 per share, in an underwritten registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to 262,500 additional shares of common stock.

Applied Therapeutics, Inc. Announces Offering of 1,750,000 Shares of Common Stock

As of late, it has definitely been a great time to be an investor Applied Therapeutics.

Applied Therapeutics Shares March Higher, Can It Continue?

Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

Applied Therapeutics Up on Positive Galactosemia Study Data

Applied Therapeutics (APLT) news for Wednesday concerning positive results from a clinical trial have APLT stock rocketing higher.
The post Applied Therapeutics News: APLT Stock Shoots 32% Higher on Positive Clinical Trial Results appeared first on InvestorPlace.

Applied Therapeutics News: APLT Stock Shoots 32% Higher on Positive Clinical Trial Results

Stellar results from a phase 2 study have investors excited about the biotech's prospects.

Here's Why Applied Therapeutics Rocketed Higher Today

Shares of Applied Therapeutics Inc. APLT, -2.06% jumped 27% in premarket trading on Wednesday after the company said it had positive results from a Phase-2 clinical trial testing AT-007 as a treatment for a rare metabolic disorder.

Applied Therapeutics' stock is up on mid-stage results for metabolic drug

AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p

Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

Aprea Therapeutics

BioNTech SE

Glaukos

Inmode Ltd

Karuna Therapeutics Inc

Nextcure

Palomar

Rapt Therapeutics Inc

Turning Point Therapeutics

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

These Were the 10 Best IPOs of 2019

NEW YORK, Dec.  16, 2019  (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board, will ring the Nasdaq Closing Bell on Tuesday, December 17, 2019, at 4:00 p.m. ET.

Applied Therapeutics to Ring Nasdaq Closing Bell on December 17th

News for Applied Therapeutics Inc Stock (APLT)